Adding Local Therapy to Immunotherapy Fails to Boost Survival in Metastatic Lung Cancer
A phase III trial found that local consolidative therapy after nivolumab plus ipilimumab did not improve overall survival or progression-free survival in metastatic non-small cell lung cancer. The median overall survival was actually shorter with the added therapy, and the study was closed early for futility. Researchers concluded that routine use of this approach is not supported outside clinical trials.
The LONESTAR trial enrolled 166 patients with stage IV non-small cell lung cancer lacking EGFR or ALK alterations, all of whom received induction nivolumab plus ipilimumab before randomization. Among those randomized to local consolidative therapy, 16 underwent surgery and 71 received radiation to at least one disease site. A post-hoc analysis linked mediastinal radiation to increased lymphopenia, which may have blunted effector immune cell activity. The study was halted early for futility, with only patients under 65 showing a potential overall survival benefit from the added local treatment.
This negative result could reshape clinical practice for metastatic NSCLC, as many oncologists may have considered adding radiation or surgery after dual immunotherapy to extend control. The finding suggests that such consolidation may not only fail to help but could harm survival, potentially sparing patients from unnecessary procedures and side effects. However, the trial’s early closure and subgroup signals mean further research is needed to identify any niche populations, such as younger patients, who might still benefit.